Shares of Versartis Inc. (VSAR) were up 4.9% to $2.05 in premarket trading on Friday, Dec. 1.
The Menlo Park, Calif.-based endocrine-focused biopharmaceutical firm on Oct. 26 said it has hired Cowen and Co. LLC to help evaluate potential transactions. On Sept. 21, the company said its Phase 3 study of somavaratan in pediatric growth hormone deficiency (GHD) did not achieve its primary endpoint.
Meanwhile, shares of Adamas Pharmaceuticals Inc. (ADMS) rose 2.7% to $38.15. The Emeryville, Calif.-based firm in August clinched the U.S. Food and Drug Administration's approval for Gocovri as a treatment for dyskinesia in Parkinson's disease patients receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Among the other biotech movers was DBV Technologies SA (DBVT) . The Montrouge, France-based firm's American depository receipts ended Thursday's trading session up 1.5% and were down 3% to $22.15 in premarket trading on Friday. On Nov. 20, DBV unveiled positive topline results from its Phase 3 Realise study of peanut allergy treatment Viaskin Peanut.
